Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
-
Zhonghua Xue Ye Xue Za Zhi · Aug 2009
Comparative Study[A comparative study on early toxicity of conditioning regimen with or without antithymocyte globulin].
To evaluate the toxicity of conditioning regimens of modified Bu/Cy +/- antithymocyte (ATG) in early stage after allogeneic hematopoietic stem cell transplantation (allo-HSCT). ⋯ Significant higher incidence of non-infectious fever, diarrhea, hepatotoxicity, leukopenia, and transfusion dependence is found and considered to be related to the administration of ATG in the conditioning regimen.
-
Zhonghua Xue Ye Xue Za Zhi · Jun 2012
Case Reports[Genotype and function analyses of four inherited dysfibrinogenemia pedigree caused by Arg16 amino acid substitution in fibrinogen Aα chain].
To analyze the phenotype, genotype and function in four Chinese pedigrees with inherited dysfibrinogenemia. ⋯ The four probands with dysfibrinogenemia were caused by the mutations of Aα chain Arg16His or Arg16Cys. Mutation of the fibrinogen induced dysfunction of plasma fibrinogen.
-
Zhonghua Xue Ye Xue Za Zhi · Mar 2014
[Bortezomib-based chemotherapy for patients with multiple myeloma: a single center experience].
To evaluate the efficacy and safety of bortezomib-based chemotherapy for 80 patients with multiple myeloma (MM). ⋯ MM patients could benefit from bortezomib-based chemotherapy with satisfactory efficacy and safety. HSCT could improve the OS for young MM patients.
-
Zhonghua Xue Ye Xue Za Zhi · Mar 2012
[A novel diagnostic measure of platelet-specific antibody in immune thrombocytopenia].
To detect the platelet glycoprotein-specific antibodies in serum of thrombocytopenia patients and evaluate its diagnostic value for immune thrombocytopenia. ⋯ The highly specific method (PAKAUTO) could effectively differentiate immune or non-immune thrombocytopenia and be applied to diagnosis of immune thrombocytopenia.
-
Zhonghua Xue Ye Xue Za Zhi · Feb 2012
[Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
To evaluated the impact of baseline ABL kinase domain point mutations on responses to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML). ⋯ Nilotinib is a more effective option for imatinib-resistant or-intolerant CML patients. Response for patients with CP was better than patients with AP and BC. Mutational status at baseline may influence response. Less sensitive mutations may be associated with less favorable responses to nilotinib.